ライフサイエンスコーパス: ankylosing spondylitis

1 aphic axial spondyloarthritis (also known as ankylosing spondylitis).

2 ic target for autoimmune diseases, including ankylosing spondylitis.

3 f exercise and nonpharmacologic therapies in ankylosing spondylitis.

4 on may be of benefit to select patients with ankylosing spondylitis.

5 psoriatic arthritis, reactive arthritis, or ankylosing spondylitis.

6 espect to understanding the genetic basis of ankylosing spondylitis.

7 pus erythematosus, rheumatoid arthritis, and ankylosing spondylitis.

8 ists are effective for signs and symptoms of ankylosing spondylitis.

9 s and spinal deformities similar to those in ankylosing spondylitis.

10 en shown to be effective in the treatment of ankylosing spondylitis.

11 dissection of the genetic susceptibility to ankylosing spondylitis.

12 otential role in delaying the progression of ankylosing spondylitis.

13 itis and to attenuate spinal inflammation in ankylosing spondylitis.

14 antagonists can prevent structural damage in ankylosing spondylitis.

15 b were also effective in phase III trials in ankylosing spondylitis.

16 thritis can be asymptomatic, as in classical ankylosing spondylitis.

17 , inflammatory bowel diseases, psoriasis, or ankylosing spondylitis.

18 or (p75):Fc fusion protein, in patients with ankylosing spondylitis.

19 , and sustained improvement in patients with ankylosing spondylitis.

20 in Sardinia, seem not to be associated with ankylosing spondylitis.

21 children or siblings of female patients with ankylosing spondylitis.

22 pathway is a potential therapeutic target in ankylosing spondylitis.

23 report human TRBV9(+) T cell elimination in ankylosing spondylitis.

24 a selective JAK1 inhibitor, in patients with ankylosing spondylitis.

25 ons like psoriasis, psoriatic arthritis, and ankylosing spondylitis.

26 been shown to be effective in patients with ankylosing spondylitis.

27 icrobiome are associated with development of ankylosing spondylitis.

28 sistent with the overall lack of efficacy in ankylosing spondylitis.

29 ondyloarthropathies, psoriatic arthritis and ankylosing spondylitis.

30 rials of secukinumab in patients with active ankylosing spondylitis.

31 ording to the modified New York criteria for ankylosing spondylitis.

32 s Crohn's disease, rheumatoid arthritis, and ankylosing spondylitis.

33 e epistatic association of both molecules in ankylosing spondylitis.

34 orm of axial spondyloarthropathies, which is ankylosing spondylitis.

35 -7.0) for psoriasis, psoriatic arthritis, or ankylosing spondylitis.

36 -B27 subtypes differentially associated with ankylosing spondylitis.

37 inflammatory diseases, notably psoriasis and ankylosing spondylitis.

38 th inflammatory bowel disease, psoriasis and ankylosing spondylitis.

39 ythematosus (1346+/-1011 pg per milliliter), ankylosing spondylitis (1368+/-1162 pg per milliliter),

40 ges of patients achieving the Assessments in Ankylosing Spondylitis 20% response (ASAS20) at weeks 12

41 improved significantly after MR imaging for ankylosing spondylitis (29% vs 80%, P < .001), undiffere

42 psoriatic arthritis (5 phase 3 trials), and ankylosing spondylitis (4 phase 3 trials).

43 ren of women had an even higher incidence of ankylosing spondylitis (7.2 [1.5-34], p=0.013) than did

44 an [SD] age, 48.8 [12.1] years), and 977 had ankylosing spondylitis (7.3%; 658 men [67.3%]; mean [SD]

45 relationship between the gut microbiome and ankylosing spondylitis, a quantitative metagenomics stud

46 Evaluating Long-Term Efficacy and Safety in Ankylosing Spondylitis, a randomized controlled study, w

47 ot disease and valve disease associated with ankylosing spondylitis (AKS).

48 Reactive arthritis, sacroiliitis, and ankylosing spondylitis also appear to be increased in th

49 residues 528 and 575/725 is associated with ankylosing spondylitis among HLA-B27-positive individual

50 riteria for PsA, a new composite measure for ankylosing spondylitis and axial SpA, the ASDAS, new mea

51 ndyloarthropathic changes closely resembling ankylosing spondylitis and DISH.

52 dies of various physical therapy programs in ankylosing spondylitis and identify their benefits and p

53 has supported novel roles for these drugs in ankylosing spondylitis and in cancer prevention, accumul

54 bserved in phase III trials of patients with ankylosing spondylitis and in trials conducted a decade

55 However, ankylosing spondylitis and inflammatory bowel disease we

56 ecent studies indicate that the morbidity of ankylosing spondylitis and PsA are considerably higher t

57 Three risk loci shared with ankylosing spondylitis and psoriasis (the MHC class I re

58 uding rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis, confirms the impor

59 clude rheumatoid arthritis, Crohn's disease, ankylosing spondylitis and psoriasis.

60 immune-mediated disorders, most notably with ankylosing spondylitis and psoriasis.

61 of the tumor necrosis factor antagonists in ankylosing spondylitis and psoriatic arthritis has gener

62 necrosis factor inhibitors for patients with ankylosing spondylitis and psoriatic arthritis has had a

63 Sulfasalazine is moderately effective for ankylosing spondylitis and psoriatic arthritis, although

64 The greatest experience has accrued in ankylosing spondylitis and psoriatic arthritis.

65 ved functional status and quality of life in ankylosing spondylitis and psoriatic arthritis.

66 als with tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis.

67 are effective and safe for the treatment of ankylosing spondylitis and psoriatic arthritis.

68 cells from healthy donors and patients with ankylosing spondylitis and psoriatic arthritis.

69 Ankylosing spondylitis and related spondylarthritides ar

70 ole for HLA-B27 in genetic susceptibility to ankylosing spondylitis and related spondyloarthropathies

71 cal comparison with originator infliximab in ankylosing spondylitis and rheumatoid arthritis; however

72 ons within major histocompatibility complex (ankylosing spondylitis and sacroiliitis, P = 1.4E-15; OR

73 absence of EIMs (eg, ankylosing spondylitis [ankylosing spondylitis and sacroiliitis], primary sclero

74 ing psoriatic arthritis, reactive arthritis, ankylosing spondylitis), and osteoarthritis have charact

75 mune-mediated diseases, including psoriasis, ankylosing spondylitis, and Behcet disease.

76 patients with systemic lupus erythematosus, ankylosing spondylitis, and hepatic fibrosis.

77 ch as rheumatoid arthritis, IgA nephropathy, ankylosing spondylitis, and inflammatory bowel disease (

78 anding inflammation in rheumatoid arthritis, ankylosing spondylitis, and juvenile chronic arthritis.

79 tion may have structure-modifying effects in ankylosing spondylitis, and may thereby alter the diseas

80 immune diseases such as behcet's disease and ankylosing spondylitis, and ocular involvement of infect

81 se, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, and osteoarthritis.

82 However, anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangit

83 nvestigated one in detail, a risk allele for ankylosing spondylitis, and provide direct evidence of a

84 indications (psoriatic arthritis, psoriasis, ankylosing spondylitis, and rheumatoid arthritis), we te

85 erextensibility, early onset osteoarthritis, ankylosing spondylitis, and seronegative erosive rheumat

86 py not only in RA but also in Crohn disease, ankylosing spondylitis, and several other chronic inflam

87 lgia rheumatica (PMR), giant cell arteritis, ankylosing spondylitis, and Sjogren's syndrome, and to p

88 e of the spondyloarthritides, including PsA, ankylosing spondylitis, and the broader categories of Sp

89 the disease-modifying role of these drugs in ankylosing spondylitis, and their use in the understudie

90 s, two patients with gout, two patients with ankylosing spondylitis, and two patients with psoriatic

91 cases with presence or absence of EIMs (eg, ankylosing spondylitis [ankylosing spondylitis and sacro

92 Patients with juvenile-onset ankylosing spondylitis appear to have poorer functional

93 or rheumatoid arthritis, where patients with ankylosing spondylitis are offered therapy early in the

94 The spondylarthritides (such as ankylosing spondylitis) are multisystem inflammatory dis

95 This group includes 6 entities: ankylosing spondylitis, arthritis associated with inflam

96 h American sample of two new loci related to ankylosing spondylitis, ARTS1 and IL23R, and confirmatio

97 systemic lupus erythematosus (SLE) (n = 10), ankylosing spondylitis (AS) (n = 10), primary Sjogren's

98 Ankylosing spondylitis (AS) affects 0.25-1.0% of the pop

99 strated similarities and differences between ankylosing spondylitis (AS) and axial psoriatic arthriti

100 s detailing their application in a number of ankylosing spondylitis (AS) and axial spondyloarthritis

101 mography (MDCT) findings of 41 patients with ankylosing spondylitis (AS) and compared them with pulmo

102 rongly associated with predisposition toward ankylosing spondylitis (AS) and other spondyloarthropath

103 e autoimmune inflammatory arthritis disorder ankylosing spondylitis (AS) and with other related spond

104 Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic inflammatory dis

105 ) affects approximately 40% of patients with ankylosing spondylitis (AS) but also affects patients wi

106 iasis (PSOR), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) from 526 subjects overall.

107 nk/ank mouse develops a phenotype similar to ankylosing spondylitis (AS) in humans.

108 tients with MRI-evident sacroiliitis develop ankylosing spondylitis (AS) in the long term and whether

109 Ankylosing spondylitis (AS) is a chronic inflammatory ar

110 Ankylosing spondylitis (AS) is a chronic inflammatory ar

111 Ankylosing spondylitis (AS) is a chronic inflammatory di

112 Ankylosing spondylitis (AS) is a common and highly famil

113 Ankylosing spondylitis (AS) is a common, highly heritabl

114 We investigated the proposal that ankylosing spondylitis (AS) is associated with unusual E

115 Ankylosing spondylitis (AS) is the prototypic form of Sp

116 erstanding of the gene-regulatory network in ankylosing spondylitis (AS) is vital for elucidating the

117 Ankylosing spondylitis (AS) may present with extra-artic

118 The clinical response in ankylosing spondylitis (AS) patients treated with biolog

119 ment of spinal inflammation in patients with ankylosing spondylitis (AS) relies primarily on magnetic

120 udies of the HLA-B27-transgenic rat model of ankylosing spondylitis (AS) suggested that macrophages d

121 A strong association between ERAP1 and ankylosing spondylitis (AS) was recently identified by t

122 seases of the spine and pelvis (for example, ankylosing spondylitis (AS)) and the eye (that is, acute

123 7 subtypes associated with susceptibility to ankylosing spondylitis (AS), and those reported not to b

124 HC) tag SNPs from 1,000 independent cases of ankylosing spondylitis (AS), autoimmune thyroid disease

125 s I molecule B27 is strongly associated with ankylosing spondylitis (AS), but the pathogenic role of

126 rated high heritability of susceptibility to ankylosing spondylitis (AS), it is only recently that th

127 ld standard of rheumatologists' diagnosis of ankylosing spondylitis (AS), psoriatic arthritis (PsA),

128 l and peripheral articular manifestations of ankylosing spondylitis (AS), psoriatic arthritis (PsA),

129 negative spondyloarthropathies (SpA) include ankylosing spondylitis (AS), psoriatic arthritis (PsA),

130 endoplasmic reticulum aminopeptidase 1) with ankylosing spondylitis (AS), which is restricted to HLA-

131 hat is necessary to establish a diagnosis of ankylosing spondylitis (AS).

132 graphic damage in patients with longstanding ankylosing spondylitis (AS).

133 ntial association with the rheumatic disease ankylosing spondylitis (AS).

134 lity of life (HRQOL) in patients with active ankylosing spondylitis (AS).

135 pathogenic role in the spondylarthropathy of ankylosing spondylitis (AS).

136 sulfapyridine (SP), in patients with active ankylosing spondylitis (AS).

137 formation manifests the clinical feature of ankylosing spondylitis (AS).

138 l disease with rheumatoid arthritis (RA) and ankylosing spondylitis (AS).

139 e treatment of osteoporosis in patients with ankylosing spondylitis (AS).

140 ss I molecules due to their association with Ankylosing Spondylitis (AS).

141 TNFis) have revolutionized the management of ankylosing spondylitis (AS); however, the lack of notabl

142 ciated with the chronic inflammatory disease Ankylosing Spondylitis (AS); however, the mechanisms und

143 ASsessment of Ankylosing Spondylitis (ASAS) International Working Grou

144 with unlike conformations in differentially ankylosing spondylitis-associated subtypes) must not be

145 initiate autoimmune damage in patients with ankylosing spondylitis-associated subtypes.

146 cant reductions in the signs and symptoms of ankylosing spondylitis at week 16.

147 a prospective study involving patients with ankylosing spondylitis, behcet's disease, presumed sarco

148 e for relieving the pain of axial disease in ankylosing spondylitis but these findings contradict two

149 eased susceptibility and disease activity of ankylosing spondylitis, but the effect of HLA-B27 on the

150 me-wide association study in 2,053 unrelated ankylosing spondylitis cases among people of European de

151 replication in an independent cohort of 898 ankylosing spondylitis cases and 1,518 controls.

152 changes in the course of the disease, Stoke Ankylosing spondylitis classification Spinal Score (SASS

153 eously investigated the genetic landscape of ankylosing spondylitis, Crohn's disease, psoriasis, prim

154 D16S516), multiple sclerosis (D12S1052), and ankylosing spondylitis (D16S516).

155 0 patients and 45 controls: alopecia areata, ankylosing spondylitis, dermatomyositis, Graves' disease

156 oth M-CSF and MMP-3 correlated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) v

157 A modified Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) w

158 cal disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),

159 onset, disease activity assessed by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),

160 ondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),

161 Disease activity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).

162 ter disease activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (P = 0.002

163 ase activity and functional parameters (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI],

164 s (EAIR, 0.02; 95% CI, 0.00-0.11), and 2 had ankylosing spondylitis (EAIR, 0.08; 95% CI, 0.01-0.28).

165 nthesitis (using the PsA-modified Maastricht Ankylosing Spondylitis Enthesitis Score [MASES] index).

166 ce of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, familial Mediterranean fever, an

167 rmatomyositis; 16 had scleroderma; eight had ankylosing spondylitis; five had juvenile RA; three had

168 ose with psoriatic arthritis, and those with ankylosing spondylitis from phase III trials of golimuma

169 Eligible patients had active ankylosing spondylitis, fulfilled modified New York crit

170 al assessments included the BASDAI, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Ank

171 ght, VAS scores for entheseal pain, the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bat

172 d functional impairment assessed by the Bath Ankylosing Spondylitis Functional Index (BASFI).

173 nal limitations were assessed using the Bath Ankylosing Spondylitis Functional Index (BASFI; score ra

174 ylitis Disease Activity Index [BASDAI], Bath Ankylosing Spondylitis Functional Index [BASFI], and Bat

175 ondylitis Functional Index [BASFI], and Bath Ankylosing Spondylitis Global Index [BASGI]).

176 etween inflammation and structural damage in ankylosing spondylitis has been an important focus of re

177 Medical therapy of ankylosing spondylitis has improved dramatically with th

178 ive arthritis, but an infectious trigger for ankylosing spondylitis has not yet been established.

179 d for patients with rheumatoid arthritis and ankylosing spondylitis have been reported, and generic q

180 esitis in psoriatic arthritis and uveitis in ankylosing spondylitis, have also been observed.

181 at has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial.

182 x in determining increased susceptibility to ankylosing spondylitis in children.

183 that TNFi slows radiographic progression in ankylosing spondylitis in data from clinical trials may

184 osome regions in human genome, which control ankylosing spondylitis in human patients.

185 irst published clinical account of a case of ankylosing spondylitis in the United States.

186 principle has relevance to diseases such as ankylosing spondylitis, in which HLA-B27 and ERAP jointl

187 une hemolytic anemia, pernicious anemia, and ankylosing spondylitis), infectious (pneumonia, hepatiti

188 f Life (ASQoL) instrument, the ASsessment in Ankylosing Spondylitis International Working Group crite

189 Ankylosing spondylitis is a common form of inflammatory

190 Ankylosing spondylitis is a genetically determined and c

191 Ankylosing spondylitis is an inflammatory autoimmune dis

192 Ankylosing spondylitis is associated with increased risk

193 IL-1A association further substantiate that ankylosing spondylitis is determined to a large extent b

194 modified New York criteria, the diagnosis of ankylosing spondylitis is made based on the presence of

195 Nearly half of the susceptibility to ankylosing spondylitis is provided by major histocompati

196 One of the major goals of treatment of ankylosing spondylitis is to prevent or slow the develop

197 The prototypical type of axSpA, ankylosing spondylitis, is thought to be caused by inter

198 rthritis, psoriasis/psoriatic arthritis, and ankylosing spondylitis) linked to newborns with periconc

199 autoimmune disease and evidence showed that ankylosing spondylitis may be a microbiome-driven diseas

200 ment in spinal mobility metrics and the Bath Ankylosing Spondylitis Metrology Index (BASMI).

201 with many immune-mediated diseases including ankylosing spondylitis, multiple sclerosis, and inflamma

202 = 8), juvenile rheumatoid arthritis (n = 3), ankylosing spondylitis (n = 1), and psoriatic spondylart

203 pproval of Janus kinase (JAK) inhibitors for ankylosing spondylitis, new data on the effect of biolog

204 , rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-infectious uveitis, and mult

205 ebo-controlled RCTs of rheumatoid arthritis, ankylosing spondylitis, optic neuritis, systemic lupus e

206 = 1.33; 95% CI, 1.03-1.72) and negative for ankylosing spondylitis (OR = 0.72; 95% CI, 0.54-0.98) an

207 d arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, or inflammatory bowel disease us

208 indications (psoriasis, psoriatic arthritis, ankylosing spondylitis, or juvenile arthritis), as an ac

209 adults diagnosed with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis and 219 h

210 wel disease, psoriasis, psoriatic arthritis, ankylosing spondylitis, or rheumatoid arthritis exhibite

211 d IL12B regions convincingly associated with ankylosing spondylitis (P < 5 x 10(-8) in the combined d

212 tients with presumed sarcoidosis compared to ankylosing spondylitis (p = 0.0001), behcet's disease (p

213 ts with presumed sarcoidosis with respect to ankylosing spondylitis (p = 0.0001), behcet's disease, (

214 dation of two new genes, IL23R and ARTS1, in ankylosing spondylitis pathogenesis.

215 shown to be differentially abundant between ankylosing spondylitis patients and healthy controls.

216 A recent trial in ankylosing spondylitis patients demonstrated continuous

217 Specifically, the ankylosing spondylitis patients demonstrated increases i

218 In ankylosing spondylitis patients, IL-6 and LRG-1 were ide

219 emic sclerosis patients and in 3 of 12 (25%) ankylosing spondylitis patients.

220 monly used in probiotics, accumulated in the ankylosing spondylitis patients.

221 e advances in the pharmacological therapy of ankylosing spondylitis, physical therapy remains an esse

222 RS had a higher significant association with ankylosing spondylitis, polymyositis, psoriasis, rheumat

223 carrying of the spinal cord in the course of ankylosing spondylitis, present in MRI include: bone mar

224 dently linked to inflammatory bowel disease, ankylosing spondylitis, primary sclerosing cholangitis a

225 n the pathogenesis or development process of ankylosing spondylitis, providing new leads for the deve

226 IBD), and psoriasis, psoriatic arthritis, or ankylosing spondylitis (psoriasis and spondyloarthropath

227 Group criteria for SpA, without evidence of ankylosing spondylitis, psoriasis, inflammatory bowel di

228 recently associated with the pathogenesis of ankylosing spondylitis, psoriatic arthritis and acute an

229 ct in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and juvenil

230 ts and for diseases other than RA, including ankylosing spondylitis, psoriatic arthritis, and polymyo

231 mmatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psorias

232 mmatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psorias

233 uded in the category of spondyloarthropathy (ankylosing spondylitis, psoriatic arthritis, reactive ar

234 ng Spondylitis Functional Index (BASFI), the Ankylosing Spondylitis Quality of Life (ASQoL) instrumen

235 the Short Form 36 (SF-36) Health Survey and Ankylosing Spondylitis Quality of Life (ASQoL) Questionn

236 tis Disease Activity Index (BASDAI), and the Ankylosing Spondylitis Quality of Life (ASQoL) questionn

237 lvis, and hips were scored by using the Bath Ankylosing Spondylitis Radiology Index (BASRI) by an exp

238 pinal radiographs were scored using the Bath Ankylosing Spondylitis Radiology Index for the spine (BA

239 ry rheumatic diseases that primarily include ankylosing spondylitis, reactive arthritis, and the arth

240 Previously, the diagnosis of ankylosing spondylitis required advanced changes on plai

241 rheumatological conditions (i.e. psoriasis, ankylosing spondylitis, rheumatoid arthritis, fibromyalg

242 keletal disorders, including osteoarthritis, ankylosing spondylitis, rheumatoid arthritis, heterotopi

243 dy reports four genetic loci associated with ankylosing spondylitis risk and identifies a major role

244 before HLA class I presentation, only affect ankylosing spondylitis risk in HLA-B27-positive individu

245 ) a random sample of members of the National Ankylosing Spondylitis Society.

246 ccess in psoriasis, psoriatic arthritis, and ankylosing spondylitis, sparking efforts to develop oral

247 bar spine, which were scored using the Stoke Ankylosing Spondylitis Spine Score.

248 biologic DMARDs on structural progression in ankylosing spondylitis, strategy trials on tapering or s

249 of the interleukin-1 (IL-1) region genes in ankylosing spondylitis suggested the susceptibility to b

250 A recent meta-analysis of published scans of ankylosing spondylitis susceptibility has confirmed site

251 on-major histocompatibility complex genes in ankylosing spondylitis susceptibility, and suggests area

252 ocompatibility complex), 10q, 16q and 19q in ankylosing spondylitis susceptibility.

253 r psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, an

254 , psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, Sj

255 c lupus erythematosus, rheumatoid arthritis, ankylosing spondylitis, systemic sclerosis, Sjogren synd

256 nt GWAS on multiple sclerosis, psoriasis and ankylosing spondylitis that inclusion of known covariate

257 able and effective structure modification in ankylosing spondylitis, the data strongly suggest a bene

258 As in human ankylosing spondylitis, the MHC was the major permissive

259 ide strong evidence that HLA-B27 operates in ankylosing spondylitis through a mechanism involving abe

260 Exercise therapy should remain a mainstay of ankylosing spondylitis treatment complementing medical t

261 durations may result in a paradigm shift for ankylosing spondylitis treatment similar to that undergo

262 gone substantial change from when the entity ankylosing spondylitis was defined by the modified New Y

263 Ankylosing spondylitis was more prevalent among children

264 To identify susceptibility loci for ankylosing spondylitis, we undertook a genome-wide assoc

265 50% and 75% of patients were diagnosed with ankylosing spondylitis were ascertained from a database

266 Forty patients with active, inflammatory ankylosing spondylitis were randomly assigned to receive

267 e SpA (2 with psoriatic arthritis and 1 with ankylosing spondylitis) were isolated by positive select

268 cantly reduces spinal inflammation in active ankylosing spondylitis when compared to placebo; there w

269 There are few effective treatments for ankylosing spondylitis, which causes substantial morbidi

270 atibility complex genes in predisposition to ankylosing spondylitis, which will be summarized here.

271 s and well tolerated in patients with active ankylosing spondylitis who had an inadequate response or

272 A 58-year-old woman with debilitating ankylosing spondylitis who was born to consanguineous pa

273 and women differ in their susceptibility to ankylosing spondylitis, with about 2.5 men affected for

274 de over 90% of the overall susceptibility to ankylosing spondylitis, with about half of the genetic c

275 esitis-related arthritis progress to develop ankylosing spondylitis within 10 years after presentatio